实施科学视角下老年2型糖尿病患者药物自我管理干预方案构建与初步应用

注册号:

Registration number:

ChiCTR2600122070 

最近更新日期:

Date of Last Refreshed on:

2026-04-08 16:47:42 

注册时间:

Date of Registration:

2026-04-08 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

实施科学视角下老年2型糖尿病患者药物自我管理干预方案构建与初步应用

Public title:

Development and Preliminary Application of Medication Self-Management Intervention Program for Older Adults with Type 2 Diabetes Mellitus from an Implementation Science Perspective

注册题目简写:

English Acronym:

研究课题的正式科学名称:

实施科学视角下老年2型糖尿病患者药物自我管理干预方案构建与初步应用

Scientific title:

Development and Preliminary Application of Medication Self-Management Intervention Program for Older Adults with Type 2 Diabetes Mellitus from an Implementation Science Perspective

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胥艳 

研究负责人:

胥艳 

Applicant:

Yan Xu 

Study leader:

Yan Xu  

申请注册联系人电话:

Applicant telephone:

+86 152 7987 6381

研究负责人电话:

Study leader's
telephone:

+86 152 7987 6381

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

3375617391@qq.com

研究负责人电子邮件:

Study leader's E-mail:

3375617391@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖南省郴州市人民西路31号

研究负责人通讯地址:

湖南省郴州市人民西路31号

Applicant address:

No. 31, Renmin West Road, Chenzhou City, Hunan Province

Study leader's address:

No. 31, Renmin West Road, Chenzhou City, Hunan Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

湘南学院附属医院

Applicant's institution:

the Affiliated Hospital of Xiangnan University

研究负责人所在单位:

湘南学院附属医院

Affiliation of the Leader:

the Affiliated Hospital of Xiangnan University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

K2026-007-01号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

湘南学院附属医院技术科研伦理委员会

Name of the ethic committee:

Clinical Research Ethics Review Opinions of the Technical Ethics Committee of the Affiliated Hospital of Xiangnan University

伦理委员会批准日期:

Date of approved by ethic committee:

2026-02-11 00:00:00

伦理委员会联系人:

王时云

Contact Name of the ethic committee:

Shiyun Wang

伦理委员会联系地址:

湖南省郴州市人民西路31号

Contact Address of the ethic committee:

No. 31, Renmin West Road, Chenzhou City, Hunan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 735 232 5232

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

湘南学院附属医院

Primary sponsor:

the Affiliated Hospital of Xiangnan University

研究实施负责(组长)单位地址:

湖南省郴州市人民西路31号

Primary sponsor's address:

No. 31, Renmin West Road, Chenzhou City, Hunan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖南省

市(区县):

郴州市

Country:

China

Province:

Hunan

City:

Chenzhou

单位(医院):

湘南学院附属医院

具体地址:

湖南省郴州市人民西路31号

Institution
hospital:

the Affiliated Hospital of Xiangnan University

Address:

No. 31, Renmin West Road, Chenzhou City, Hunan Province

经费或物资来源:

课题组经费

Source(s) of funding:

Rsearch group fund

研究疾病:

2型糖尿病  

Target disease:

type 2 diabetes mellitus

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

旨在基于实施科学视角,构建一套适用于老年2型糖尿病患者的药物自我管理干预方案,并在临床实际中验证其可行性及效果,以提升患者的药物自我管理水平与用药依从性,为老年糖尿病规范化用药管理与延续性护理提供循证依据和实践参考。  

Objectives of Study:

The purpose is to construct a set of mdedication self-management intervention programs suitable for elderly patients with type 2 diabetes mellitus based on the perspective of implementation science, and to verify its feasibility and effect in clinical practice, so as to improve the level of medication self-management and medication adherence of patients, and provide evidence-based basis and practical reference for standardized medication management and continuous care of elderly diabetes

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.研究期间出现严重急性并发症或病情明显恶化者; 2.合并严重心血管、肝肾、神经系统疾病或精神系统疾病,影响自我管理能力者; 3.存在影响药物服用或参与度的其他疾病(如晚期肿瘤等); 4.正在参加其他药物管理或健康教育干预研究的患者。

Exclusion criteria:

1. Those who have severe acute complications or significantly worsen their condition during the study; 2. Those who have severe cardiovascular, hepatic, renal, neurological or mental system diseases that affect their self-management ability; 3. Other diseases that affect drug use or participation (such as advanced tumors, etc.); 4. Patients who are participating in other drug management or health education intervention studies.

研究实施时间:

Study execute time:

From 2026-04-15 00:00:00 To 2027-01-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-04-15 00:00:00 To 2026-07-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

40

Group:

Observation Group

Sample size:

干预措施:

给予常规护理及健康教育

干预措施代码:

Intervention:

Routine nursing and health education are provided

Intervention code:

组别:

实验组

样本量:

40

Group:

Intervention Group

Sample size:

干预措施:

在对照组的基础上采用老年2型糖尿病患者实施老年2型糖尿病患者药物自我管理干预方案。

干预措施代码:

Intervention:

On the basis of the control group, elderly patients with type 2 diabetes were used to implement the drug self-management intervention program for elderly patients with type 2 diabetes.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖南省  

市(区县):

 

Country:

China

Province:

Hunan

City:

单位(医院):

湘南学院附属医院 

单位级别:

三甲 

Institution
hospital:

the Affiliated Hospital of Xiangnan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

药物自我管理

指标类型:

主要指标

Outcome:

medication self-management

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

服药依从性

指标类型:

主要指标

Outcome:

medication adherence

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

用药知识

指标类型:

次要指标

Outcome:

Medication knowledge

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

合理用药自我效能

指标类型:

次要指标

Outcome:

Rational medication self-efficacy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

可及性

指标类型:

次要指标

Outcome:

Accessibility

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

采纳性

指标类型:

次要指标

Outcome:

Adoptability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 60 years
最大 Max age 99 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

nothing

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

nothing

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表、电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form,lectronic Data Capture(HIS)

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-04-08 16:46:32